78. 下垂体前葉機能低下症 Hypopituitarism Clinical trials / Disease details
臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05355272 (ClinicalTrials.gov) | June 2023 | 20/4/2022 | Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | Growth Hormone Replacement Therapy in Veterans With Gulf War Illness and Adult Growth Hormone Deficiency | Gulf War Syndrome;Adult Growth Hormone Deficiency | Drug: Recombinant human growth hormone;Drug: Placebo | Baylor College of Medicine | United States Department of Defense | Not yet recruiting | 18 Years | 64 Years | All | 36 | Phase 2 | United States |
| 2 | NCT04867317 (ClinicalTrials.gov) | May 1, 2023 | 8/4/2021 | Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | CSP #2018 - Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | Adult Growth Hormone Deficiency;Mild Traumatic Brain Injury | Drug: Somatropin;Other: Placebo | VA Office of Research and Development | NULL | Not yet recruiting | 21 Years | 55 Years | All | 172 | Phase 3 | United States |
| 3 | NCT04121780 (ClinicalTrials.gov) | October 8, 2019 | 25/9/2019 | Growth Hormone Replacement Therapy for Retried Professional Football Players | Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency | TBI (Traumatic Brain Injury);Concussion, Brain;Sport Injury;Anterior Pituitary Hyposecretion Syndrome;Hypopituitarism;Growth Hormone Deficiency | Biological: Growth Hormone;Other: Placebo | Center for Neurological Studies | Novo Nordisk A/S | Recruiting | 18 Years | 76 Years | Male | 42 | Phase 2 | United States |
| 4 | NCT02243852 (ClinicalTrials.gov) | September 2014 | 16/9/2014 | Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) | Evaluation of the Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) Concentration in Patients With Growth Hormone Deficiency (GHD) | Growth Hormone Deficiency | Drug: Growth Hormone Replacement Therapy | University of Liverpool | Pfizer | Recruiting | 18 Years | 80 Years | Both | 48 | N/A | United Kingdom |
| 5 | EUCTR2012-005066-36-NL (EUCTR) | 15/05/2013 | 23/01/2013 | To investigate the effect of different doses of Growth Hormone treatment on the risk of developing cardiovascular diseases in patients with growth hormone deficiency | Effect of Growth Hormone replacement therapy on cardiovascular risk factors in adult patients with severe growth hormone deficiency: association with IGF-I concentration - GH and cardiovascular risk factors | Growth hormone deficiency;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Genotropin Trade Name: Norditropin Trade Name: Humatrope Trade Name: Zomacton | VU University Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 6 | NCT01877512 (ClinicalTrials.gov) | May 2013 | 11/6/2013 | GH and Cardiovascular Risk Factors | Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration | Growth Hormone Deficiency;Cardiovascular Diseases;Metabolic Syndrome;Cognition;Physical Activity | Drug: Change in daily dosage of Growth Hormone | VU University Medical Center | NULL | Completed | 20 Years | 65 Years | Both | 32 | Phase 4 | Netherlands |
| 7 | NCT00630487 (ClinicalTrials.gov) | May 2008 | 28/2/2008 | Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency | Prospective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study) | Growth Hormone Deficiency | Drug: Placebo;Drug: Somatropin | Pfizer | NULL | Terminated | 18 Years | 65 Years | All | 9 | Phase 3 | Germany |
| 8 | NCT00555009 (ClinicalTrials.gov) | March 2008 | 24/10/2007 | Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury | Placebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury. | Brain Injuries;Growth Hormone Deficiency | Drug: Genotropin;Drug: Placebo | Pfizer | NULL | Terminated | 18 Years | 55 Years | All | 10 | Phase 4 | France;Italy;Netherlands;Spain;Sweden;United Kingdom |
| 9 | EUCTR2007-003586-41-FR (EUCTR) | 13/02/2008 | 14/11/2007 | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Growth hormone deficiency after traumatic brain injury MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Genotropin/GENOTONORM® Product Name: Genotropin/GENOTONORM® | Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 120 | United Kingdom;Netherlands;France;Spain;Italy;Sweden | |||
| 10 | EUCTR2007-000790-36-DE (EUCTR) | 08/01/2008 | 12/12/2007 | Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study) - PRO ISO-GHD Study | Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study) - PRO ISO-GHD Study | Isolated Adult Growth Hormone Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Genotropin 5 mg/ml INN or Proposed INN: Somatropin Trade Name: Genotropin 5 mg/ml INN or Proposed INN: Somatropin | Pfizer Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 50 | Germany | |||
| 11 | EUCTR2007-003586-41-NL (EUCTR) | 17/12/2007 | 09/08/2007 | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Growth hormone deficiency after traumatic brain injury MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Genotropin Product Name: Genotropin | Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 120 | United Kingdom;Netherlands;France;Spain;Italy;Sweden | |||
| 12 | EUCTR2007-003586-41-ES (EUCTR) | 26/11/2007 | 20/11/2007 | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injuryEnsayo controlado con placebo sobre la eficacia del tratamiento de reposición de hormona de crecimiento en pacientes con déficit de hormona de crecimiento después de un traumatismo cerebral. - N/A | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injuryEnsayo controlado con placebo sobre la eficacia del tratamiento de reposición de hormona de crecimiento en pacientes con déficit de hormona de crecimiento después de un traumatismo cerebral. - N/A | Tratamiento del déficit de hormona de crecimiento en adultos después de un traumatismo cerebral. MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) Product Name: Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin) INN or Proposed INN: Somatropina | Pfizer, S.A | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 4 | France;Spain;Netherlands;Italy;United Kingdom;Sweden | ||
| 13 | EUCTR2007-003586-41-SE (EUCTR) | 21/11/2007 | 12/09/2007 | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Growth hormone deficiency after traumatic brain injury MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Genotropin Product Name: Genotropin | Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 120 | United Kingdom;Netherlands;France;Spain;Italy;Sweden | |||
| 14 | EUCTR2007-003586-41-GB (EUCTR) | 15/11/2007 | 11/10/2007 | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Placebo-controlled trial on the efficacy of growth hormone replacement therapy inpatients with growth hormone deficiency after traumatic brain injury - N/A | Growth hormone deficiency after traumatic brain injury MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Genotropin Product Name: Genotropin | Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | NULL | Not Recruiting | Female: yes Male: yes | 120 | United Kingdom;Netherlands;France;Spain;Italy;Sweden | |||
| 15 | NCT00491582 (ClinicalTrials.gov) | July 2007 | 25/6/2007 | The Effects of Growth Hormone (GH) on Lipid Depots | The Effect of Growth Hormone (GH) on Intramyocellular Lipids (IMCL), Intrahepatocellular Lipids (IHCL) and Visceral Fat Mass in Relation to Insulin Resistance | Growth Hormone Deficiency | Drug: Growth hormone replacement therapy in growth hormone deficient patients only. | University Hospital Inselspital, Berne | Swiss National Science Foundation | Completed | 18 Years | 80 Years | Both | 34 | N/A | Switzerland |
| 16 | NCT00432263 (ClinicalTrials.gov) | April 2007 | 5/2/2007 | Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury. | Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury | Brain Injuries | Drug: Genotropin (PN-180,307) Somatropin | Pfizer | NULL | Withdrawn | 18 Years | 55 Years | Both | 0 | Phase 4 | NULL |
| 17 | NCT01576861 (ClinicalTrials.gov) | January 2007 | 19/3/2012 | Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure | Growth Hormone Deficiency;Chronic Heart Failure | Drug: Somatotropin | Federico II University | NULL | Completed | 18 Years | 80 Years | Both | 28 | Phase 2 | Italy | |
| 18 | NCT01698944 (ClinicalTrials.gov) | May 16, 2001 | 1/10/2012 | Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency | Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency | Growth Hormone Disorder;Adult Growth Hormone Deficiency | Drug: somatropin | Novo Nordisk A/S | NULL | Terminated | 12 Years | 25 Years | All | 7 | Phase 4 | Greece |